In recent years, with the rapid development of technology, the Beacon Optofluidic System, as an advanced cell manipulation and detection technology, has provided a new perspective and tool for the research of tumor immunotherapy. This system not only greatly promotes the progress of tumor microenvironment research, but also provides scientific basis for the development of personalized treatment plans. This article will delve into the role of Beacon single-cell optical fiber system in tumor immunotherapy, and analyze in detail its applications in precision medicine, drug development, and new therapy development.

1、Technical characteristics of Beacon Optofluidic System

Beacon Optofluidic System is a cell manipulation and detection technology based on optical methods. It uses laser beams to precisely manipulate cells, including laser microbeads, laser scanning, laser-induced emission, etc., to achieve precise control and manipulation of cells. At the same time, the system also utilizes optical detection technology for real-time monitoring and detection of cells, including scattered light detection, fluorescence detection, Raman spectroscopy detection, etc., to obtain detailed information inside the cells. This unique technological feature makes the Beacon Optofluidic System have broad application prospects in the biomedical field.

1. Precise manipulation and real-time monitoring: The Beacon Optofluidic System can accurately manipulate tumor cells and microenvironment components, such as stromal cells, immune cells, etc., simulate different microenvironment conditions, and observe the growth, proliferation, and metastasis behavior of tumor cells under these conditions. At the same time, the system can also monitor the dynamic changes in the tumor microenvironment in real time, such as the expression levels of bioactive molecules such as growth factors and cytokines, as well as the activity of immune cells. This ability enables researchers to gain a deeper understanding of the mechanisms by which the tumor microenvironment affects tumor cells, providing a foundation for developing more effective treatment plans.

2. High throughput and high sensitivity: The Beacon Optofluidic System integrates optoelectronic positioning technology and microfluidic technology to achieve high-throughput single-cell based cell biology research in the nano upgrade chamber of the chip. The system is capable of processing thousands of single cells simultaneously and supports multiple chip types to meet the experimental needs of different fluxes. In addition, due to the very small volume of NanoPen (only 0.5-1 nl), a single cell is placed in it with a density equivalent to 1E6 cell/ml, making it easy to detect and highly sensitive.

3. Automation and ease of operation: The Beacon Optofluidic System has the characteristic of full automation, from cell introduction, cultivation, cloning, subcloning, detection to screening, all of which are automated processes, greatly avoiding possible errors or mistakes caused by manual operations. At the same time, the system also has an easy-to-use software interface, touch screen operation, flexible and intuitive graphical interface design, and is easy to use.

2、Application of Beacon Optofluidic System in Tumor Immunotherapy

1. Improve research accuracy and efficiency: The Beacon Optofluidic System improves the accuracy and efficiency of tumor microenvironment research through precise manipulation and real-time monitoring technology. In the field of tumor immunotherapy, this technology can quickly screen and validate new treatment strategies, accelerating the research process. For example, researchers can use this system to simulate different tumor microenvironment conditions, observe changes in drug sensitivity of tumor cells under different conditions, and reveal the relationship between tumor microenvironment and drug sensitivity, providing a basis for developing personalized treatment plans.

2. Promote the development of personalized treatment: The complexity of the tumor microenvironment makes different patients' tumors have different characteristics and treatment needs. The Beacon Optofluidic System can simulate the tumor microenvironment conditions of different patients, evaluate the effectiveness of different treatment strategies, and provide a basis for developing personalized treatment plans. For example, in TCR-T cell therapy, researchers can use the system to identify TCRs targeting autologous myeloma cells, identify reactive T cells by detecting secreted cytokines and surface expression, and clone their TCR genes for the preparation and functional validation of tumor specific T cells. This personalized treatment can not only improve the treatment effect, but also reduce unnecessary side effects and complications, and improve the quality of life of patients.

3. Expand the new field of tumor immunotherapy: The application of Beacon Optofluidic System is not limited to the traditional field of tumor immunotherapy, but can also be extended to new areas. For example, the system can be used to study the interaction between the tumor microenvironment and the immune system, as well as the relationship between the tumor microenvironment and metabolic pathways. These new fields of research will contribute to a more comprehensive understanding of the role of the tumor microenvironment in tumor development, providing new ideas and methods for tumor treatment. For example, researchers can use this system to study the mechanism of KRAS mutations in tumors and develop TCRm antibodies targeting KRAS mutation targets, providing new avenues for solid tumor treatment.

4. Promote the development and evaluation of new drugs: The Beacon Optofluidic System can also be used for the development and evaluation of new drugs. By simulating different tumor microenvironment conditions and observing changes in drug sensitivity of tumor cells under different conditions, researchers can evaluate the efficacy and safety of new drugs. In addition, the system can also be used for drug screening and optimization, accelerating the drug development process by quickly screening antibody drugs with ideal structures and activities. For example, in the screening of antiviral neutralizing antibodies, researchers can use this system to enrich B cells from the blood of recovered patients, and perform single B cell level screening and sequencing to quickly and efficiently obtain antiviral neutralizing antibodies.

3、Specific case analysis

1. TCR-T cell therapy research at the German Cancer Research Center: The German Cancer Research Center uses the Bruker Optofluidic System (similar to the Beacon system) to identify tumor specific T cells for personalized T cell therapy development. The research team used the OptoSelect 1500 chip to perform functional analysis on up to 1500 individual T cell/target cell interactions, identifying reactive T cells by detecting secreted cytokines and surface expression. Subsequently, they cloned the TCR gene of tumor reactive T cells and overexpressed it in autologous T cells for functional validation and analysis of tumor derived new epitope specificity. This study provides important scientific evidence for the development of TCR-T cell therapy and demonstrates the enormous potential of the Beacon Optofluidic System in tumor immunotherapy.

2. Research on KRAS mutation target TCRM antibody of Baiaosaitu: Baiaosaitu company used the RenTCR mimicTM patented mouse model for immunization, and combined it with a high-throughput screening platform based on Beacon single-cell optical technology, successfully identified a batch of novel TCRM antibodies with high specificity for G12V/HLA and G12D/HLA complexes. These antibodies have stronger affinity and help reduce the risk of tumors evading immune surveillance. Phylogenetic analysis shows that these antibodies have high sequence diversity and potential targeting of different epitopes. In addition, when these TCSm antibodies were assembled into CD3 T cell adapters, they demonstrated strong tumor killing activity in vitro experiments and demonstrated excellent safety through rigorous testing. This study provides new ideas and methods for the treatment of KRAS mutation targets.

The Beacon Optofluidic System, as an advanced cell manipulation and detection technology, has played an important role in the field of tumor immunotherapy. Through precise manipulation and real-time monitoring technology, the system has improved the accuracy and efficiency of research, promoted the development of personalized therapy, and expanded the new field of tumor immunotherapy. With the emergence of the Beacon Optofluidic System from Redbert (Beijing) Biotechnology Co., Ltd., it saves you a lot of time and greatly reduces production costs. The Beacon Optofluidic System can intervene when the cell diversity and survival rate are optimal after transfection, and it is easy to screen multiple cells and select cell lines with higher expression levels, greatly reducing subsequent production costs. We have reason to believe that the Beacon Optofluidic System will play a greater role in tumor immunotherapy, bringing more hope and possibilities for tumor treatment. At the same time, we also look forward to more new technologies and methods constantly emerging to jointly promote the progress and development of oncology research.

* The above content is collected online for reference only. If the articles on this website involve copyright or other issues, please contact us promptly and we will handle them as soon as possible.